A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

213

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2029

Conditions

DFS

Interventions

DRUG

Chemotherapy combined with immunization

MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy

Trial Locations (1)

Xuanwu Hospital, Beijing

All Listed Sponsors

lead

Xuanwu Hospital, Beijing

OTHER